Clinical Trial Update: Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial [Phase 2]

View source ↗

Summary

A Phase 2 double-blind, placebo-controlled trial evaluating anti-estrogen therapy for hereditary hemorrhagic telangiectasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Anti-estrogen therapy

Snippet

Sponsor: Rabin Medical Center | Conditions: Hereditary Hemorrhagic Telangiectasia | Phase 2 | Status: COMPLETED